Latest Research And Development News

AML3D has maintained a steady $2.2 million quarterly revenue run rate and secured $12.5 million in new orders during 3Q26, pushing its total orders for FY2026 to $29 million. The company is aggressively expanding its US manufacturing footprint and making initial inroads into UK and European defence markets.

Harvest Technology Group sharpened its international defence focus in Q1 2026, onboarding NATO and commercial clients to its Nodestream platform, progressing new video features, and appointing Jeff Sengelman as Executive Chair amid CEO transition.

Stakk Ltd (ASX: SKK) has delivered a striking 272% jump in gross receipts to $5.36 million in Q3 FY26, reversing prior cash outflows with a positive net cash flow of $2.25 million and closing the quarter with $17.34 million in cash.

Invex Therapeutics reported promising preclinical findings on Exenatide’s effects in a human Alzheimer's disease model, alongside a steady cash position and reduced operating outflows in Q3 FY26.

Noxopharm signed a strategic MoU with Tezcat Biosciences, published major Sofra RNA research, and appointed Dr Olivier Laczka as CEO, while reporting positive safety data from its HERACLES trial and improving cash flow.

Phoslock Environmental Technologies reported a stable sales volume and improved cash flow compared to last year, while ramping up production after reopening its Chinese factory. The company is advancing R&D on a new lanthanum product and faces ongoing legal challenges with mediation set for June.

BPH Global’s Indonesian arm has entered Stage 2 of its collaboration with Indonesia’s National Research and Innovation Agency to develop fucoidan extraction technology and a powdered supplement prototype, targeting commercialisation within months.

Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.

BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.

Advanced Braking Technology Ltd (ASX: ABV) reported a 28% jump in product sales revenue to $6 million for Q3 FY26, driven by strong aftermarket sales and international market traction. The company also advanced certification of its autonomous BRAKEiQ system, targeting FY27 adoption.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

Neometals has secured A$7.9 million through a placement and launched a concurrent A$5.1 million entitlement offer to fund gold production at Barrambie and advance lithium exploration in Utah. The capital raise supports a near-term production joint venture and aggressive resource expansion.